期刊
CELLS
卷 10, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/cells10081871
关键词
brain derived neurotrophic factor; nerve growth factor; TrkA; TrkB; cognition; Alzheimer's disease
类别
资金
- Alzheimer's Drug Discovery Foundation [20151003]
- Vinnova [2014-00347]
- Swedish Brain Power
- Swedish Brain Foundation (Hjarnfonden)
- Swedish Research Council [2016-02317, 2018-02843]
- Margaretha af Ugglas Foundation
- Stockholm County Council
- Karolinska Institutet
- Chemical Biology Consortium Sweden (CBCS), SciLifeLab, Sweden
- Karolinska High Throughput Center (KHTC)
- Swedish Research Council [2018-02843] Funding Source: Swedish Research Council
The research team has identified a novel mechanism to modulate the activity of Trk receptors, and demonstrated that ACD855 and ACD856 act as cognitive enhancers in various behavioral models, showing significant effects on 18-month-old mice and potentially having implications for the treatment of Alzheimer's disease and other cognitive impairment diseases.
Alzheimer's disease (AD) is the most common neurodegenerative disorder and results in severe neurodegeneration and progressive cognitive decline. Neurotrophins are growth factors involved in the development and survival of neurons, but also in underlying mechanisms for memory formation such as hippocampal long-term potentiation. Our aim was to identify small molecules with stimulatory effects on the signaling of two neurotrophins, the nerve growth factor (NGF) and the brain derived neurotrophic factor (BDNF). To identify molecules that could potentiate neurotrophin signaling, 25,000 molecules were screened, which led to the identification of the triazinetrione derivatives ACD855 (Ponazuril) and later on ACD856, as positive allosteric modulators of tropomyosin related kinase (Trk) receptors. ACD855 or ACD856 potentiated the cellular signaling of the neurotrophin receptors with EC50 values of 1.9 and 3.2 or 0.38 and 0.30 mu M, respectively, for TrkA or TrkB. ACD855 increased acetylcholine levels in the hippocampus by 40% and facilitated long term potentiation in rat brain slices. The compounds acted as cognitive enhancers in a TrkB-dependent manner in several different behavioral models. Finally, the age-induced cognitive dysfunction in 18-month-old mice could be restored to the same level as found in 2-month-old mice after a single treatment of ACD856. We have identified a novel mechanism to modulate the activity of the Trk-receptors. The identification of the positive allosteric modulators of the Trk-receptors might have implications for the treatment of Alzheimer's diseases and other diseases characterized by cognitive impairment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据